Literature DB >> 32262676

Evaluation of osteogenesis and angiogenesis of icariin loaded on micro/nano hybrid structured hydroxyapatite granules as a local drug delivery system for femoral defect repair.

Yuqiong Wu1, Lunguo Xia, Yuning Zhou, Wudi Ma, Na Zhang, Jiang Chang, Kaili Lin, Yuanjin Xu, Xinquan Jiang.   

Abstract

Icariin has been identified to promote osteogenic differentiation of bone mesenchymal stem cells (BMSCs). However, whether icariin could enhance angiogenic factor expression of BMSCs, which may be vital for bone repair, needs to be explored. Moreover, how to construct a delivery system of icariin and its repair capability in bone defects are still unknown. In the present study, the effects of icariin on the osteogenic differentiation and angiogenic factor expression of BMSCs were firstly evaluated. Moreover, new micro/nano hybrid structured HAp (micro/nano HAp) granules were fabricated to construct the delivery system of icariin, and the osteogenesis and angiogenesis of icariin loaded on micro/nano HAp granules in a rat femoral plug defect model were evaluated by micro-CT measurements, sequential fluorescent labeling and the histological assay. The in vitro results showed that icariin significantly improved osteogenic differentiation of rat BMSCs demonstrated by the enhanced alkaline phosphatase (ALP) activity and gene expression of runt-related transcription factor-2 (Runx2), ALP, collagen type I (Col I), osteocalcin (OCN) and OCN protein secretion. Moreover, icariin induced the angiogenic genes expression of BMSCs, such as vascular endothelial growth factor (VEGF) and angiotensin 1 (ANG1). Furthermore, the activation of the AKT signaling pathway was observed in BMSCs upon treatment with icariin, and these enhancement effects could be blocked by LY294002, which suggested that the AKT signaling pathway was involved in the osteogenic differentiation and angiogenic factor expression of BMSCs induced by icariin. More importantly, micro/nano HAp granules with rod-like shapes were successfully fabricated and acted as delivery carriers for icariin. Consequently, icariin loaded on micro/nano HAp granules could promote new bone formation and blood vessel formation. These results demonstrated that icariin could enhance osteogenic differentiation and angiogenic factor expression of BMSCs via the AKT signaling pathway, moreover, the novel micro/nano HAp granules could act as carriers for icariin to repair bone defects via enhancing osteogenesis and angiogenesis.

Entities:  

Year:  2015        PMID: 32262676     DOI: 10.1039/c5tb00621j

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN: 2050-750X            Impact factor:   6.331


  5 in total

Review 1.  Nanotechnology for angiogenesis: opportunities and challenges.

Authors:  Saeid Kargozar; Francesco Baino; Sepideh Hamzehlou; Michael R Hamblin; Masoud Mozafari
Journal:  Chem Soc Rev       Date:  2020-06-15       Impact factor: 54.564

Review 2.  Hydrogel Encapsulation of Mesenchymal Stem Cells and Their Derived Exosomes for Tissue Engineering.

Authors:  Parisa Khayambashi; Janaki Iyer; Sangeeth Pillai; Akshaya Upadhyay; Yuli Zhang; Simon D Tran
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

3.  The osteogenesis of Ginsenoside Rb1 incorporated silk/micro-nano hydroxyapatite/sodium alginate composite scaffolds for calvarial defect.

Authors:  Yuqiong Wu; Jiahui Du; Qianju Wu; Ao Zheng; Lingyan Cao; Xinquan Jiang
Journal:  Int J Oral Sci       Date:  2022-02-14       Impact factor: 24.897

4.  TiO2 Nanotubes Functionalized with Icariin for an Attenuated In Vitro Immune Response and Improved In Vivo Osseointegration.

Authors:  Andreea-Mariana Negrescu; Valentina Mitran; Wanda Draghicescu; Simona Popescu; Cristian Pirvu; Iuliana Ionascu; Teodoru Soare; Seralp Uzun; Sorin Mihai Croitoru; Anisoara Cimpean
Journal:  J Funct Biomater       Date:  2022-04-14

5.  Bioactive natural compounds as potential medications for osteogenic effects in a molecular docking approach.

Authors:  Yuqiong Wu; Yulan Liu; Yuanjin Xu; Ao Zheng; Jiahui Du; Lingyan Cao; Junfeng Shi; Xinquan Jiang
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.